ketamine has been researched along with Affective Disorders in 50 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This narrative review describes the evolution of ketamine to treat mood disorders and suicidality." | 9.22 | Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. ( Kritzer, MD; Lai, CS; Masand, PS; Mathew, SJ; Mischel, NA; Szabo, ST; Young, JR, 2022) |
| "Replicated clinical trials have demonstrated rapid and robust antidepressant effects with ketamine in treatment resistant mood disorders." | 9.22 | Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review. ( Benitah, K; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Meshkat, S; Nasri, F; Rodrigues, NB; Rosenblat, JD; Siegel, AN, 2022) |
| " Many studies have demonstrated the efficacy of ketamine in reducing depressive symptoms in adults with treatment-resistant mood disorders, though few studies utilizing ketamine in youth populations exist." | 9.12 | A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. ( Kim, S; Rice, TR; Rush, BS, 2021) |
| " Studies of oral ketamine for depression, from case series to randomized clinical trials, were eligible." | 9.05 | An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. ( Frye, MA; Joseph, B; Kung, S; Nuñez, NA; Pahwa, M; Prokop, LJ; Schak, KM; Seshadri, A; Singh, B; Vande Voort, JL, 2020) |
| "Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment." | 8.95 | A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. ( Frye, MA; Mathew, SJ; McDonald, W; Nemeroff, CB; Sanacora, G; Schatzberg, AF; Summergrad, P; Turner, MS, 2017) |
| "Ketamine, an NMDA receptor antagonist with efficacy as a rapid anti-depressant, has early evidence for action to reduce suicidal ideation." | 8.93 | Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior. ( Mallick, F; McCullumsmith, CB, 2016) |
| " In this article, we report the case of a Canadian patient who was actively requesting Medical Assistance in Dying for severe and prolonged treatment-resistant depression until she experienced remarkable benefits from a course of intravenous ketamine infusions." | 8.31 | Ketamine for depression: a potential role in requests for Medical Aid in Dying? ( Garel, N; Greenway, KT; Looper, K; Naghi, K; Nazon, M; Rej, S; Willis, E, 2023) |
| "Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid antidepressant effect, and intranasal (IN) esketamine has been recently approved in several countries for treating depression." | 8.12 | Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. ( Brennan, S; Chokka, P; Katzman, MA; Khullar, A; Klassen, LJ; Swainson, J; Tanguay, RL, 2022) |
| "Data were obtained from 110 individuals with mood disorders (predominantly major depressive disorder) who underwent intravenous ketamine infusion." | 7.88 | Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. ( Davidson, L; Sanacora, G; Silverman, WK; van Schalkwyk, GI; Wilkinson, ST, 2018) |
| " The most common treatment-emergent adverse events associated with ketamine/esketamine are dissociation, anxiety, nausea, increased blood pressure, and headache." | 6.72 | Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. ( Cao, B; Ceban, F; Chau, EH; Gill, H; Ho, RC; Kratiuk, K; Kumar, A; Lee, JG; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Swainson, J, 2021) |
| "Ketamine is a highly attractive candidate for developing fast-onset antidepressant agents; however, the relevant brain circuits that underlie sustained, efficacious antidepressant effects remain largely unknown." | 5.43 | Large-Scale Persistent Network Reconfiguration Induced by Ketamine in Anesthetized Monkeys: Relevance to Mood Disorders. ( Hou, B; Hu, H; Jiang, Q; Li, G; Lv, Q; Pu, J; Shen, Z; Wang, Z; Yang, L; Yu, W, 2016) |
| "Electronic databases were searched to capture randomised control trials measuring the anxiolytic effects of ketamine in contexts including mood disorders, anxiety disorders and chronic pain." | 5.41 | A transdiagnostic systematic review and meta-analysis of ketamine's anxiolytic effects. ( Alexander, L; Hartland, H; Jelen, LA; Mahdavi, K; Strawbridge, R; Young, AH, 2023) |
| " Informed by the literature, which reports robust antisuicidal and antidepressive properties of subanaesthetic doses of ketamine, this review aims to provide an examination of the neurobiology of suicidality (and relevant mood disorders) with implications of pertinent animal, clinical, and postmortem studies." | 5.41 | Insights into the neurobiology of suicidality: explicating the role of glutamatergic systems through the lens of ketamine. ( Bennett, M; Can, AT; Dutton, M; Hermens, DF; Lagopoulos, J; Mitchell, JS, 2023) |
| "This narrative review describes the evolution of ketamine to treat mood disorders and suicidality." | 5.22 | Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress. ( Kritzer, MD; Lai, CS; Masand, PS; Mathew, SJ; Mischel, NA; Szabo, ST; Young, JR, 2022) |
| "Replicated clinical trials have demonstrated rapid and robust antidepressant effects with ketamine in treatment resistant mood disorders." | 5.22 | Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review. ( Benitah, K; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Meshkat, S; Nasri, F; Rodrigues, NB; Rosenblat, JD; Siegel, AN, 2022) |
| " Many studies have demonstrated the efficacy of ketamine in reducing depressive symptoms in adults with treatment-resistant mood disorders, though few studies utilizing ketamine in youth populations exist." | 5.12 | A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. ( Kim, S; Rice, TR; Rush, BS, 2021) |
| " Studies of oral ketamine for depression, from case series to randomized clinical trials, were eligible." | 5.05 | An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. ( Frye, MA; Joseph, B; Kung, S; Nuñez, NA; Pahwa, M; Prokop, LJ; Schak, KM; Seshadri, A; Singh, B; Vande Voort, JL, 2020) |
| "Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment." | 4.95 | A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. ( Frye, MA; Mathew, SJ; McDonald, W; Nemeroff, CB; Sanacora, G; Schatzberg, AF; Summergrad, P; Turner, MS, 2017) |
| "Available evidence indicates that a single, low-dose administration of ketamine is a robust, rapid-onset intervention capable of mitigating depressive symptoms in adults with treatment-resistant mood disorders." | 4.93 | A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect. ( Cha, DS; Lee, Y; Mansur, RB; Maruschak, NA; McIntyre, RS; Rosenblat, JD; Syeda, K; Wium-Andersen, IK; Woldeyohannes, HO, 2016) |
| " After a brief description of the intracellular transduction pathways implicated in both GSK-3β and mood disorders, we reviewed the results demonstrating GSK-3β involvement in the effects of lithium and ketamine." | 4.93 | The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature. ( Costemale-Lacoste, JF; Gaillard, R; Guilloux, JP, 2016) |
| "Ketamine, an NMDA receptor antagonist with efficacy as a rapid anti-depressant, has early evidence for action to reduce suicidal ideation." | 4.93 | Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior. ( Mallick, F; McCullumsmith, CB, 2016) |
| " In this article, we report the case of a Canadian patient who was actively requesting Medical Assistance in Dying for severe and prolonged treatment-resistant depression until she experienced remarkable benefits from a course of intravenous ketamine infusions." | 4.31 | Ketamine for depression: a potential role in requests for Medical Aid in Dying? ( Garel, N; Greenway, KT; Looper, K; Naghi, K; Nazon, M; Rej, S; Willis, E, 2023) |
| "Intravenous (IV) ketamine is increasingly used off-label at subanesthetic doses for its rapid antidepressant effect, and intranasal (IN) esketamine has been recently approved in several countries for treating depression." | 4.12 | Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing. ( Brennan, S; Chokka, P; Katzman, MA; Khullar, A; Klassen, LJ; Swainson, J; Tanguay, RL, 2022) |
| "Data were obtained from 110 individuals with mood disorders (predominantly major depressive disorder) who underwent intravenous ketamine infusion." | 3.88 | Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. ( Davidson, L; Sanacora, G; Silverman, WK; van Schalkwyk, GI; Wilkinson, ST, 2018) |
| "Reports of rapid-onset but short-duration antidepressant effects in patients with treatment-resistant mood disorders after intravenous administration of ketamine have prompted efforts to find an agent with ketamine's properties that can be administered orally in repeated doses in order to sustain that action." | 3.79 | Mechanism of action of dextromethorphan/quinidine:comparison with ketamine. ( Stahl, SM, 2013) |
| "Ketamine induced a range of perceptual distortions, but not hallucinations." | 3.73 | Psychological effects of ketamine in healthy volunteers. Phenomenological study. ( Absalom, AR; Bullmore, ET; Corlett, PR; Fletcher, PC; Honey, GD; Lee, M; McKenna, PJ; Murray, GK; Pomarol-Clotet, E, 2006) |
| "Ketamine has emerged as a rapid-acting antidepressant, though controversy remains whether sufficient data exist to justify its use outside of research protocols." | 2.87 | Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. ( Katz, RB; Ostroff, RB; Sanacora, G; Toprak, M; Webler, R; Wilkinson, ST, 2018) |
| " The most common treatment-emergent adverse events associated with ketamine/esketamine are dissociation, anxiety, nausea, increased blood pressure, and headache." | 2.72 | Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders. ( Cao, B; Ceban, F; Chau, EH; Gill, H; Ho, RC; Kratiuk, K; Kumar, A; Lee, JG; Lee, Y; Lin, K; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Nasri, F; Rodrigues, NB; Rosenblat, JD; Subramaniapillai, M; Swainson, J, 2021) |
| "Riluzole has been shown to reverse glutamate-mediated impairments in neuronal plasticity and to stimulate the synthesis of brain derived neurotrophic factor." | 2.43 | Glutamate modulators as novel interventions for mood disorders. ( Keegan, K; Mathew, SJ; Smith, L, 2005) |
| "Ketamine is a highly attractive candidate for developing fast-onset antidepressant agents; however, the relevant brain circuits that underlie sustained, efficacious antidepressant effects remain largely unknown." | 1.43 | Large-Scale Persistent Network Reconfiguration Induced by Ketamine in Anesthetized Monkeys: Relevance to Mood Disorders. ( Hou, B; Hu, H; Jiang, Q; Li, G; Lv, Q; Pu, J; Shen, Z; Wang, Z; Yang, L; Yu, W, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (10.00) | 29.6817 |
| 2010's | 26 (52.00) | 24.3611 |
| 2020's | 19 (38.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mathai, DS | 1 |
| McCathern, AG | 1 |
| Guzick, AG | 1 |
| Schneider, SC | 1 |
| Weinzimmer, SA | 1 |
| Cepeda, SL | 1 |
| Garcia-Romeu, A | 1 |
| Storch, EA | 1 |
| Vestring, S | 1 |
| Domschke, K | 1 |
| Normann, C | 1 |
| Bottemanne, H | 1 |
| Baldacci, A | 1 |
| Muller, C | 1 |
| Boyreau, A | 1 |
| Claret, A | 1 |
| Swainson, J | 2 |
| Klassen, LJ | 1 |
| Brennan, S | 1 |
| Chokka, P | 1 |
| Katzman, MA | 1 |
| Tanguay, RL | 1 |
| Khullar, A | 1 |
| Kritzer, MD | 1 |
| Mischel, NA | 1 |
| Young, JR | 1 |
| Lai, CS | 1 |
| Masand, PS | 2 |
| Szabo, ST | 1 |
| Mathew, SJ | 4 |
| Benitah, K | 1 |
| Siegel, AN | 1 |
| Lipsitz, O | 4 |
| Rodrigues, NB | 4 |
| Meshkat, S | 1 |
| Lee, Y | 5 |
| Mansur, RB | 4 |
| Nasri, F | 4 |
| Lui, LMW | 4 |
| McIntyre, RS | 5 |
| Rosenblat, JD | 5 |
| Klein, ME | 1 |
| Grice, AB | 1 |
| Sheth, S | 1 |
| Go, M | 1 |
| Murrough, JW | 2 |
| Hartland, H | 1 |
| Mahdavi, K | 1 |
| Jelen, LA | 1 |
| Strawbridge, R | 1 |
| Young, AH | 1 |
| Alexander, L | 1 |
| Garel, N | 1 |
| Nazon, M | 1 |
| Naghi, K | 1 |
| Willis, E | 1 |
| Looper, K | 1 |
| Rej, S | 1 |
| Greenway, KT | 1 |
| Can, AT | 1 |
| Mitchell, JS | 1 |
| Dutton, M | 1 |
| Bennett, M | 1 |
| Hermens, DF | 1 |
| Lagopoulos, J | 1 |
| Hashimoto, K | 2 |
| Kim, S | 1 |
| Rush, BS | 1 |
| Rice, TR | 1 |
| Kavalali, ET | 1 |
| Monteggia, LM | 1 |
| Carvalho, IP | 1 |
| Majeed, A | 1 |
| Gill, H | 3 |
| Coles, AC | 1 |
| Tamura, JK | 1 |
| Iacobucci, M | 1 |
| Phan, L | 1 |
| Singhal, N | 1 |
| Wong, ER | 1 |
| Subramaniapillai, M | 3 |
| Mansur, R | 1 |
| Ho, R | 2 |
| Lam, RW | 1 |
| Munkholm, K | 1 |
| Jørgensen, KJ | 1 |
| Nuñez, NA | 1 |
| Joseph, B | 1 |
| Pahwa, M | 1 |
| Seshadri, A | 1 |
| Prokop, LJ | 1 |
| Kung, S | 1 |
| Schak, KM | 1 |
| Vande Voort, JL | 1 |
| Frye, MA | 2 |
| Singh, B | 1 |
| Ng, J | 1 |
| Teopiz, KM | 1 |
| Cha, DS | 2 |
| Xiong, J | 1 |
| Kratiuk, K | 2 |
| Cao, B | 2 |
| Reddy, BR | 1 |
| Babu, NS | 1 |
| Das, T | 1 |
| Bhattacharya, D | 1 |
| Murthy, CLN | 1 |
| Kumar, A | 2 |
| Idris, MM | 1 |
| Chakravarty, S | 1 |
| Ceban, F | 1 |
| Lee, JG | 1 |
| Chau, EH | 1 |
| Lin, K | 1 |
| Ho, RC | 1 |
| Sanacora, G | 7 |
| Golzari, SEJ | 1 |
| Mahmoodpoor, A | 1 |
| Rasmussen, KG | 1 |
| Kraus, C | 1 |
| Lanzenberger, R | 1 |
| Kasper, S | 1 |
| Wilkinson, ST | 3 |
| van Schalkwyk, GI | 1 |
| Davidson, L | 1 |
| Silverman, WK | 1 |
| Neehoff, S | 1 |
| Glue, P | 1 |
| Vranjkovic, O | 1 |
| Winkler, G | 1 |
| Winder, DG | 1 |
| Katz, RB | 1 |
| Toprak, M | 1 |
| Webler, R | 1 |
| Ostroff, RB | 1 |
| De Berardis, D | 1 |
| Fornaro, M | 1 |
| Valchera, A | 1 |
| Cavuto, M | 1 |
| Perna, G | 1 |
| Di Nicola, M | 1 |
| Serafini, G | 1 |
| Carano, A | 1 |
| Pompili, M | 1 |
| Vellante, F | 1 |
| Orsolini, L | 1 |
| Fiengo, A | 1 |
| Ventriglio, A | 1 |
| Yong-Ku, K | 1 |
| Martinotti, G | 1 |
| Di Giannantonio, M | 1 |
| Tomasetti, C | 1 |
| Stahl, SM | 1 |
| Niciu, MJ | 1 |
| Mathews, DC | 1 |
| Nugent, AC | 1 |
| Ionescu, DF | 1 |
| Furey, ML | 1 |
| Richards, EM | 1 |
| Machado-Vieira, R | 3 |
| Zarate, CA | 4 |
| Tang, WK | 1 |
| Morgan, CJ | 1 |
| Lau, GC | 1 |
| Liang, HJ | 1 |
| Tang, A | 1 |
| Ungvari, GS | 1 |
| Schatzberg, AF | 2 |
| Abdallah, CG | 1 |
| Duman, RS | 1 |
| Krystal, JH | 1 |
| Carlezon, WA | 1 |
| George, TP | 1 |
| DeWilde, KE | 1 |
| Levitch, CF | 1 |
| Iosifescu, DV | 1 |
| Stuart, SA | 1 |
| Butler, P | 1 |
| Munafò, MR | 1 |
| Nutt, DJ | 1 |
| Robinson, ES | 1 |
| Lv, Q | 1 |
| Yang, L | 1 |
| Li, G | 1 |
| Wang, Z | 2 |
| Shen, Z | 1 |
| Yu, W | 1 |
| Jiang, Q | 1 |
| Hou, B | 1 |
| Pu, J | 1 |
| Hu, H | 1 |
| Syeda, K | 1 |
| Maruschak, NA | 1 |
| Wium-Andersen, IK | 1 |
| Woldeyohannes, HO | 1 |
| Costemale-Lacoste, JF | 1 |
| Guilloux, JP | 1 |
| Gaillard, R | 1 |
| Mallick, F | 1 |
| McCullumsmith, CB | 1 |
| McDonald, W | 1 |
| Turner, MS | 1 |
| Summergrad, P | 1 |
| Nemeroff, CB | 1 |
| Manji, HK | 1 |
| Loo, CK | 1 |
| Katalinic, N | 1 |
| Garfield, JB | 1 |
| Sainsbury, K | 1 |
| Hadzi-Pavlovic, D | 1 |
| Mac-Pherson, R | 1 |
| Keegan, K | 1 |
| Smith, L | 1 |
| Pomarol-Clotet, E | 1 |
| Honey, GD | 1 |
| Murray, GK | 1 |
| Corlett, PR | 1 |
| Absalom, AR | 1 |
| Lee, M | 1 |
| McKenna, PJ | 1 |
| Bullmore, ET | 1 |
| Fletcher, PC | 1 |
| Stone, JM | 1 |
| Pilowsky, LS | 1 |
| Maeng, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Music as a Potential Intervention to Improve Hemodynamic Tolerability of Repetitive Sub-Anesthetic IV Ketamine Infusions in Bipolar and Unipolar Depression: A Pilot Study[NCT04701866] | 32 participants (Actual) | Interventional | 2021-01-11 | Completed | |||
| University of Iowa Interventional Psychiatry Service Patient Registry[NCT04480918] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2020-11-02 | Recruiting | |||
| A Double-blind Randomised, Placebo-controlled Study of Adjunctive Ketamine Anaesthesia in ECT (Electroconvulsive Therapy)[NCT00680433] | Phase 4 | 83 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Evaluation of the Initial Prescription of Ketamine and Milnacipran Forin Depression in Patients With a Progressive Disease[NCT02783430] | Phase 2/Phase 3 | 80 participants (Anticipated) | Interventional | 2016-09-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
25 reviews available for ketamine and Affective Disorders
| Article | Year |
|---|---|
[Ketamine and other N-methyl-D-aspartate receptor modulators in treatment of depression].
Topics: Antidepressive Agents; Depression; Humans; Ketamine; Mood Disorders; Receptors, N-Methyl-D-Aspartate | 2022 |
Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
Topics: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Meta-Analysi | 2022 |
Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review.
Topics: Antidepressive Agents; Female; Humans; Ketamine; Male; Mood Disorders; Sex Characteristics; Sex Fact | 2022 |
A transdiagnostic systematic review and meta-analysis of ketamine's anxiolytic effects.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Depression; Humans; Ketamine; Mood Disorders | 2023 |
Insights into the neurobiology of suicidality: explicating the role of glutamatergic systems through the lens of ketamine.
Topics: Animals; Antidepressive Agents; Humans; Ketamine; Mood Disorders; Suicidal Ideation; Suicide | 2023 |
A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.
Topics: Adolescent; Adult; Antidepressive Agents; Bipolar Disorder; Child; Depressive Disorder, Treatment-Re | 2021 |
Targeting Homeostatic Synaptic Plasticity for Treatment of Mood Disorders.
Topics: Animals; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatm | 2020 |
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2020 |
An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis.
Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Female; Humans; Ketamine; Male | 2020 |
Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disor | 2021 |
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders.
Topics: Administration, Intranasal; Administration, Intravenous; Antidepressive Agents; Anxiety; Disease Man | 2021 |
[Biomarkers for Mood Disorders and a Novel Antidepressant (R)-ketamine].
Topics: Antidepressive Agents; Biomarkers; Cytokines; Humans; Ketamine; Meta-Analysis as Topic; Mood Disorde | 2017 |
Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors.
Topics: Depressive Disorder; Humans; Ketamine; Mood Disorders; Suicidal Ideation; Suicide Prevention | 2018 |
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants.
Topics: Analgesics; Antidepressive Agents; Biomarkers; Cholinergic Antagonists; Genomics; Humans; Ketamine; | 2014 |
Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?
Topics: Animals; Antidepressive Agents; Drug Discovery; Excitatory Amino Acid Antagonists; Glutamic Acid; Hu | 2015 |
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.
Topics: Antidepressive Agents; Brain; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2015 |
The promise of ketamine for treatment-resistant depression: current evidence and future directions.
Topics: Anhedonia; Antidepressive Agents; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatm | 2015 |
A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect.
Topics: Adult; Cognition; Depressive Disorder, Treatment-Resistant; Excitatory Amino Acid Antagonists; Human | 2016 |
The role of GSK-3 in treatment-resistant depression and links with the pharmacological effects of lithium and ketamine: A review of the literature.
Topics: Antidepressive Agents; Depressive Disorder, Treatment-Resistant; Enzyme Inhibitors; Glycogen Synthas | 2016 |
Ketamine for Treatment of Suicidal Ideation and Reduction of Risk for Suicidal Behavior.
Topics: Depression; Depressive Disorder; Humans; Ketamine; Mood Disorders; Receptors, N-Methyl-D-Aspartate; | 2016 |
Ketamine: translating mechanistic discoveries into the next generation of glutamate modulators for mood disorders.
Topics: Animals; Excitatory Amino Acid Antagonists; Humans; Ketamine; Mood Disorders | 2017 |
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders.
Topics: Anxiety Disorders; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Evide | 2017 |
The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.
Topics: Animals; Brain; Excitatory Amino Acid Antagonists; Glutamic Acid; Humans; Ketamine; Mood Disorders; | 2009 |
Glutamate modulators as novel interventions for mood disorders.
Topics: Animals; Antidepressive Agents; Excitatory Amino Acid Antagonists; Humans; Ketamine; Mood Disorders; | 2005 |
The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects.
Topics: Amantadine; Depressive Disorder, Major; Dopamine Agents; Excitatory Amino Acid Antagonists; Humans; | 2007 |
2 trials available for ketamine and Affective Disorders
| Article | Year |
|---|---|
Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Treatment-Re | 2018 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial.
Topics: Adult; Affect; Bipolar Disorder; Cognition; Cognition Disorders; Depressive Disorder, Major; Double- | 2012 |
23 other studies available for ketamine and Affective Disorders
| Article | Year |
|---|---|
Parental Attitudes Toward Use of Ketamine in Adolescent Mood Disorders and Suicidality.
Topics: Adolescent; Attitude; Bipolar Disorder; Child; Decision Making; Depressive Disorder, Major; Female; | 2021 |
[Ketamine Augmented Psychotherapy (KAP) in mood disorder: User guide].
Topics: Antidepressive Agents; Dissociative Disorders; Humans; Ketamine; Mood Disorders; Psychotherapy | 2022 |
Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing.
Topics: Antidepressive Agents; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood | 2022 |
Pharmacological Treatments for Anhedonia.
Topics: Anhedonia; Brain; Depressive Disorder, Major; Humans; Ketamine; Mood Disorders; Reward | 2022 |
Ketamine for depression: a potential role in requests for Medical Aid in Dying?
Topics: Canada; Depression; Female; Humans; Ketamine; Mood Disorders; Suicide, Assisted | 2023 |
Brain-derived neurotrophic factor-TrkB signaling and the mechanism of antidepressant activity by ketamine in mood disorders.
Topics: Animals; Antidepressive Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Humans; Ketamin | 2020 |
No evidence for the effectiveness of IV ketamine for treatment resistant mood disorders in retrospective study.
Topics: Adult; Anxiety; Bipolar Disorder; Depressive Disorder, Major; Depressive Disorder, Treatment-Resista | 2020 |
Proteome profile of telencephalon associates attenuated neurogenesis with chronic stress induced mood disorder phenotypes in zebrafish model.
Topics: Affect; Animals; Antidepressive Agents; Anxiety; Cell Proliferation; Depression; Disease Models, Ani | 2021 |
Ketamine for the Treatment of Depression-Reply.
Topics: Consensus; Depression; Depressive Disorder, Major; Humans; Ketamine; Mood Disorders | 2017 |
Ketamine for the Treatment of Depression.
Topics: Consensus; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disorders | 2017 |
Ketamine for the Treatment of Depression.
Topics: Consensus; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disorders | 2017 |
Ketamine for the Treatment of Depression.
Topics: Consensus; Depression; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mood Disorders | 2017 |
Considerations on the Off-label Use of Ketamine as a Treatment for Mood Disorders.
Topics: Advisory Committees; Anesthetics, Dissociative; Chronic Disease; Humans; Ketamine; Mood Disorders; O | 2017 |
Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Factor Analysis, Statistical; Female; Huma | 2018 |
Dissociation after ketamine dosing: Is the CADSS fit for purpose?
Topics: Dissociative Disorders; Double-Blind Method; Humans; Ketamine; Mood Disorders | 2019 |
Ketamine administration during a critical period after forced ethanol abstinence inhibits the development of time-dependent affective disturbances.
Topics: Affect; Alcohol-Related Disorders; Animals; Disease Models, Animal; Female; Ketamine; Long-Term Pote | 2018 |
Mechanism of action of dextromethorphan/quinidine:comparison with ketamine.
Topics: Dextromethorphan; Drug Combinations; Excitatory Amino Acid Antagonists; Humans; Ketamine; Mood Disor | 2013 |
Psychiatric morbidity in ketamine users attending counselling and youth outreach services.
Topics: Adolescent; Adult; Anxiety Disorders; Comorbidity; Counseling; Depressive Disorder; Excitatory Amino | 2015 |
Circumspectives: the promise of ketamine.
Topics: Animals; Antidepressive Agents; Humans; Ketamine; Mood Disorders | 2015 |
Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy.
Topics: Animals; Antidepressive Agents; Association Learning; Brain; Cannabinoid Receptor Antagonists; Carbo | 2015 |
Large-Scale Persistent Network Reconfiguration Induced by Ketamine in Anesthetized Monkeys: Relevance to Mood Disorders.
Topics: Animals; Antidepressive Agents; Brain; Brain Mapping; Female; Ketamine; Macaca fascicularis; Macaca | 2016 |
Psychological effects of ketamine in healthy volunteers. Phenomenological study.
Topics: Adult; Brief Psychiatric Rating Scale; Central Nervous System; Cognition Disorders; Delusions; Excit | 2006 |
Psychopathological consequences of ketamine.
Topics: Adult; Brief Psychiatric Rating Scale; Delusions; Excitatory Amino Acid Antagonists; Female; Halluci | 2006 |